Multiple Myeloma 2021

Nina Shah, MD, discusses breakthroughs in the treatment of multiple myeloma throughout the preceding year.

Nina Shah, MD, highlights some of the major takeaways in multiple myeloma from the 2021 European Hematology Association Congress.

Nina Shah, MD, touched on important abstracts being presented at the 2021 American Society of Hematology Annual Meeting.

Nina Shah, MD, discusses the biggest news from the FDA for multiple myeloma in the past year.

Nina Shah, MD, on the current treatment options for treating patients with transplant-eligible multiple myeloma.

Nina Shah, MD, discusses the current treatment options for treating patients with transplant-ineligible multiple myeloma.

Nina Shah, MD, discusses how to properly navigate treatment plans for patients with relapsed/refractory multiple myeloma.

Nina Shah, MD, discussed how adverse events impact treatment decision-making for patients with multiple myeloma.

Nina Shah, MD, on BCMA-directed treatments for patients with multiple myeloma.

Nina Shah, MD, details the process to choose optimal therapeutic options for patients with relapsed/refractory multiple myeloma.

Nina Shah, MD, touched on novel immunotherapies and other emerging therapies for patients with multiple myeloma.

Nina Shah, MD, discusses some of the important phase 3 trials to emerge from the previous year in multiple myeloma.

Nina Shah, MD, discusses maintenance therapies in emerging clinical trials for multiple myeloma.

Nina Shah, MD, looks to the future of treating patients with multiple myeloma.

Nina Shah, MD, discusses the potential therapies that could emerge in 2022 for multiple myeloma.